Regen BioPharma Inc (OTC: RGBP) is a pre-revenue biopharmaceutical company that develops RNA interference-based therapeutics and cellular therapies targeting cancer immunology. The company has not generated significant revenues as of the fiscal year ended September 30, 2025, and its intended revenue model is future royalty and licensing income from agreements with outside entities commercializing its drug candidates. RGBP operates through itself and a wholly owned subsidiary, KCL. Its pipeline includes DiffronC, an shRNA-based drug that inhibits expression of the NR2F6 transcription factor to activate immune cells against tumors, and DuraCar, a CAR-T cell therapy incorporating NR2F6-targeting shRNA. Both candidates were in pre-clinical development as of the 10-K filed December 30, 2025. The company operates at a net loss, carries convertible debt obligations including a 6% convertible promissory note of $100,000 principal issued to Labrys Fund II LP in August 2025, and has funded operations partly through equity issuances. David R. Koos serves as Chairman, Chief Executive Officer, and Acting Chief Financial Officer.

Revenue model

No revenue has been generated as of fiscal year ended September 30, 2025. The intended model is royalty and licensing income from third-party licensing and sublicensing agreements covering drug candidates developed by Regen and/or KCL.

Products and services

DiffronC: shRNA-based drug inhibiting NR2F6 transcription factor expression to enhance immune cell tumor-killing activity; in pre-clinical testing as of the December 30, 2025 filing. DuraCar: CAR-T cell therapy combining patient-derived CAR-T cells with NR2F6-targeting shRNA to improve tumoricidal function; in development as of the same filing.

Customers and end markets

No commercial customers as of fiscal year ended September 30, 2025. Target end market is oncology, specifically solid tumor immunotherapy.

Value-chain role

Early-stage drug discovery and pre-clinical development. The company intends to out-license or sublicense developed assets to third parties for commercialization rather than manufacture or sell therapeutics directly.

Source: SEC 10-K, filed 2025-12-30

Industry: Pharmaceutical Preparations